文献速递肝病消化道肿瘤与早癌

慢性乙型肝炎不确定期的组织学严重程度、临床结局及抗病毒治疗的影响:系统评价与荟萃分析

Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: A systematic review and meta-analysis.
PubMed 文献 · J Hepatol · 2024-11-20

该系统评价与荟萃分析纳入103项研究,评估慢性乙型肝炎不确定期患者的不良临床结局发生率及抗病毒治疗的影响。不确定期患者肝细胞癌年发生率为0.32%,抗病毒治疗与肝细胞癌风险降低相关(调整发病率比0.38)。

要点

  • 不确定期患者肝细胞癌年发生率为0.32%,肝硬化年发生率为0.67%,肝失代偿年发生率为0.34%。
  • 抗病毒治疗与不确定期患者肝细胞癌风险降低相关(调整发病率比0.38)。
  • 中重度炎症、显著纤维化、进展期纤维化和肝硬化的合并患病率分别为40.7%、39.7%、17.9%和7.2%。

核心结论

  • 不确定期患者存在进展为晚期肝病和肝细胞癌的风险,抗病毒治疗可能降低高危亚组患者发生肝细胞癌的风险。

研究设计与样本

  • 系统评价与荟萃分析,检索Embase、MEDLINE、Web of Science和中国知网2007年1月1日至2023年12月31日的文献。
  • 纳入103项研究:70项病例对照研究(18,739例患者)、32项队列研究(15,118例患者)和1项随机对照试验(160例患者)。

主要发现

  • 不确定期患者肝细胞癌年发生率为0.32%(95%CI 0.21-0.48%,I²=85.7%)。
  • 肝硬化年发生率为0.67%(95%CI 0.30-1.49%,I²=94.3%),肝失代偿年发生率为0.34%(95%CI 0.17-0.69%,I²=51.8%)。
  • 中重度肝脏炎症、显著纤维化、进展期纤维化和肝硬化的合并患病率分别为40.7%、39.7%、17.9%和7.2%。
  • 使用抗病毒治疗与不确定期患者肝细胞癌风险降低相关(调整发病率比0.38,95%CI 0.18-0.79,p=0.009)。

关键数值与推荐

  • 当前国际指南推荐对慢性乙型肝炎不确定期患者进行密切监测和评估,并对不良结局高风险患者进行治疗。

临床怎么用

  • 基于研究间存在显著异质性,证据尚不足以支持将治疗扩大至所有不确定期患者,抗病毒治疗可能降低高危亚组患者发生肝细胞癌的风险。

局限性

  • 研究间存在固有异质性,限制了支持将治疗扩大至所有不确定期患者的证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Current international guidelines recommend close monitoring and evaluation of patients with chronic hepatitis B (CHB) in the indeterminate phase, and treatment of patients at high risk of adverse outcomes. Clinical outcomes and the effect of antiviral therapy on the indeterminate phase remain unclear. We performed a systematic review and meta-analysis to study the incidence of adverse clinical outcomes including hepatocellular carcinoma (HCC), cirrhosis, and hepatic decompensation, and the effect of antiviral therapy, in the indeterminate phase. METHODS: Two investigators independently searched Embase, MEDLINE, Web of Science and China National Knowledge Infrastructure from 1/1/2007 to 31/12/2023. Three investigators independently assessed study eligibility and quality. We included cohort studies and a randomised-controlled trial, allowing for calculation of the incidence rate of adverse clinical outcomes, and cross-sectional studies that reported the prevalence of moderate-to-severe inflammation and different degrees of fibrosis. Incidence rates and prevalence were pooled using generalised linear mixed-effects models and random-effects models, respectively. RESULTS: One hundred and three studies (70 case-control studies [18,739 patients], 32 cohort studies [15,118 patients], and one RCT [160 patients]) were included. The annual incidence rate of HCC in patients in the indeterminate phase was 0.32% (95% CI 0.21-0.48%, I2 = 85.7%), and those of cirrhosis and hepatic decompensation were 0.67% (95% CI 0.30-1.49%, I2 = 94.3%) and 0.34% (95% CI 0.17-0.69%, I2 = 51.8%), respectively. The pooled prevalence of moderate-to-severe liver inflammation, significant fibrosis, advanced fibrosis, and cirrhosis was 40.7%, 39.7%, 17.9%, and 7.2%, respectively. Use of antiviral therapy was associated with a lower risk of HCC in patients in the indeterminate phase (adjusted incidence rate ratio 0.38, 95% CI 0.18-0.79, p = 0.009). CONCLUSIONS: Patients in the indeterminate phase are at risk of developing advanced liver disease and HCC. Although inherent heterogeneity across studies limited the evidence to support expanding treatment to all patients in the indeterminate phase, antiviral therapy may reduce the risk of HCC development in high-risk subgroups. IMPACT AND IMPLICATIONS: Current international guidelines recommend close monitoring and evaluation of patients with chronic hepatitis B (CHB) in the indeterminate phase, in whom antiviral treatment is not always indicated. Based on the systematic review and meta-analysis with significant heterogeneity across studies, patients in the indeterminate phase are at risk of developing hepatocellular carcinoma, cirrhosis, and hepatic decompensation. Meta-regression findings on platelet count, positive HBeAg, and age highlighted the importance of liver fibrosis assessment, accurate phase classification, and timely detection of phase transition to identify antiviral treatment indications, supporting current guideline recommendations. Antiviral treatment may reduce the risk of hepatocellular carcinoma in the high-risk subgroups of patients in the indeterminate phase. PROSPERO REGISTRATION NUMBER: CRD42024537095.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Lai JC, Wong GL, Tse YK, et al. Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: A systematic review and meta-analysis. J Hepatol. 2024. PMID: 39577468. doi:10.1016/j.jhep.2024.11.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。